Y Intercept Hong Kong Ltd Has $873,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

Y Intercept Hong Kong Ltd decreased its position in Royalty Pharma plc (NASDAQ:RPRX) by 18.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,853 shares of the biopharmaceutical company’s stock after selling 7,200 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Royalty Pharma were worth $873,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Royalty Pharma in the second quarter valued at about $254,000. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma in the second quarter valued at about $32,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Royalty Pharma by 6.7% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 993,578 shares of the biopharmaceutical company’s stock valued at $26,201,000 after acquiring an additional 62,218 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Royalty Pharma by 6.0% in the second quarter. Bank of New York Mellon Corp now owns 1,533,094 shares of the biopharmaceutical company’s stock valued at $40,428,000 after acquiring an additional 86,248 shares during the last quarter. Finally, State of Michigan Retirement System increased its position in shares of Royalty Pharma by 40.3% in the second quarter. State of Michigan Retirement System now owns 16,700 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 4,800 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Citigroup lowered their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Trading Up 0.0 %

Royalty Pharma stock opened at $25.21 on Friday. Royalty Pharma plc has a 52 week low of $25.02 and a 52 week high of $31.66. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market capitalization of $14.85 billion, a P/E ratio of 13.06, a PEG ratio of 4.55 and a beta of 0.46. The stock has a 50-day simple moving average of $26.77 and a 200 day simple moving average of $27.23.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.